Expertise in
5
conditions

Dr. Lukas D. Wartman

Oncology
Office
4921 Parkview Pl Ste 7A, 
Saint Louis, MO 
Expertise in
5
conditions
Office
4921 Parkview Pl Ste 7A, 
Saint Louis, MO 

Overview

Lukas Wartman is an Oncologist practicing medicine in Saint Louis, Missouri.

Dr. Wartman is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Promyelocytic Leukemia, Leukemia, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 13 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
4921 Parkview Pl Ste 7A, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Enrollment Status: Terminated
Publish Date: May 06, 2026
Intervention Type: Drug, Procedure
Study Drug: Duvelisib
Study Phase: Phase 2
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Enrollment Status: Active_not_recruiting
Publish Date: March 02, 2026
Intervention Type: Procedure
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other, Procedure
Study Drug: Itacitinib
Study Phase: Phase 1
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: January 17, 2024
Intervention Type: Procedure, Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, ALT-803, Cytokine-Induced Natural Killer T Cells, IL-2
Study Phase: Phase 1/Phase 2
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: ApoGraft
Study Phase: Phase 1
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 1
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Enrollment Status: Withdrawn
Publish Date: March 11, 2022
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Procedure, Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

34 Total Publications

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.
Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.
Journal: NEJM evidence
Published: August 25, 2026
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.9 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nancy Bartlett is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Bartlett is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration. Dr. Bartlett is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Office

4500 Forest Park Ave Fl 6, 
Saint Louis, MO 
 (1.5 miles away)
314-747-1171
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Neha Mehta is an Oncologist practicing medicine in Saint Louis, Missouri. She has been practicing medicine for over 17 years. Dr. Mehta is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Mehta is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Gamma Knife Of Saint Louis

4921 Parkview Pl, 
Saint Louis, MO 
 (0.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Morgensztern is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Morgensztern is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Morgensztern is currently accepting new patients.

Frequently Asked Questions about Dr. Lukas D. Wartman

How do I make an appointment with Dr. Lukas D. Wartman?

You can book an appointment with Dr. Lukas D. Wartman by calling their office at 800-647-2098. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lukas D. Wartman a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lukas D. Wartman is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lukas D. Wartman specialize in?

While Dr. Lukas D. Wartman is a Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Acute Promyelocytic Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Lukas D. Wartman participate in research or clinical trials?

Yes. Dr. Lukas D. Wartman has published 34 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Lukas D. Wartman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wartman's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile